The Peptic Ulcers drugs in development market research report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peptic Ulcers. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued products.

GlobalData tracks 28 drugs in development for Peptic Ulcers by 27 companies/universities/institutes. The top development phase for Peptic Ulcers is phase i with 11 drugs in that stage. The Peptic Ulcers pipeline has 27 drugs in development by companies and one by universities/ institutes. Some of the companies in the Peptic Ulcers pipeline products market are: Jiangsu Carephar Pharmaceutical, Hanmi Pharmaceuticals and Jiangsu Sinorda Biomedicine.

The key targets in the Peptic Ulcers pipeline products market include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19), Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1), and Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1).

The key mechanisms of action in the Peptic Ulcers pipeline product include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19) Inhibitor with 13 drugs in Pre-Registration. The Peptic Ulcers pipeline products include four routes of administration with the top ROA being Oral and one key molecule types in the Peptic Ulcers pipeline products market including Small Molecule.

Peptic Ulcers overview

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach, and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes, and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotics, acid blockers, antacids, and proton pump inhibitors.

For a complete picture of Peptic Ulcers’s pipeline drug market, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.